On 27 April 2021, the European Parliament (EP), meeting in plenary session, adopted a Decision on the conclusion of an interinstitutional agreement between the EP, the Council of the EU and the European Commission on a mandatory transparency register for all lobbyists.

The report won broad support, with 646 MEPs voting in favor, four against and 49 abstaining.

Source: Politico

#SustainablePublicAffairs: Daan van Apeldoorn is now a consultant focusing on the circular economy, energy and climate

Amazon: Eirini Zafeiratou has left Amazon and is now vice president for corporate communications and government affairs at Zalando.

amfori: Christian Ewert, president of amfori, has announced that he will step down as leader of the international business association in June.

April 21, 2021

Geopolitcal considerations

The strategy has the overall goal of ensuring Europe’s supply of safe and affordable medicines and supporting the European pharmaceutical industry’s innovation efforts.

European Commission roadmap

Medicines for Europe represents the pharmaceutical companies supplying the largest share of medicines across Europe and is the voice of the generic, biosimilar and value added industries. Medicines for Europe members’ portfolio cover 80% of therapy areas, and in so doing, safeguards the sustainability of Europe’s healthcare systems for future generations.

Member Companies-Full Members

Restrictions on Appointees Leaving Government

The Biden Executive Order imposes three “revolving door” bans on appointees who leave the federal government:

Le Dictionnaire Explicatif du Lobbying DE FOULOY est un ouvrage de référence mis à jour sur l'art du lobbying et de la défense d'intérêts et représente une version élargie du Guide de réference du lobbyiste professionnel publié à l'origine sous le titre anglais 'The Professional Lobbyist's Desk Reference' ainsi que la deuxième édition du 'Fouloy's Explanatory Lobbying Dictionary'. 

Commercial agreements typically specify specific standards in describing the degree of effort that a party is expected to undertake in order to carry out certain contractual obligations. For example, in many contracts, reference is made to one or the other party to the contract undertaking its "best efforts," "reasonable efforts" or "commercially reasonable efforts." Often, much time and attention is devoted to negotiating which of these standards will apply. Nevertheless, ambiguities remain as to the precise meaning of each of such standards.

What is proposed hereunder is the creation of a web-based system called ‘CHARLEMAGNE ’ that would be a forum for lobbyists, constituents, and other interested parties to come together to publicly and transparently debate legislation, and in the process provide EU staff, journalists, and the public access to the best available arguments, information, and ideas about public policy – all in a way that is easily searchable and sortable. In order to make CHARLEMAGNE easily navigable, different types of participants should use the system in different ways.

EuropaBio represents 45 corporate and associate members, and 19 national  associations and Bioregions

Corporate Members